Environmental chemical exposures and human epigenetics

International Journal of Epidemiology

Volumn 41, Issue 1, 2012, Pages 79-105

  Hou, Lifang ^a   Zhang, Xiao ^a   Wang, Dong ^a,b   Baccarelli, Andrea ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Disease susceptibility; Environmental chemicals; Epigenetics

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ARSENIC; BENZENE; CADMIUM; CYCLONITE; DIETHYLSTILBESTROL; DIOXIN; DRINKING WATER; ENVIRONMENTAL CHEMICAL; HEAVY METAL; MERCURY; MICRORNA; NICKEL; PESTICIDE;

BIOINFORMATICS; BIOMARKER; CHEMICAL POLLUTANT; DISEASE INCIDENCE; DISEASE PREVALENCE; ENVIRONMENTAL FATE; EPIDEMIOLOGY; ETIOLOGY; FUTURE PROSPECT; GENETIC VARIATION; HEALTH RISK; LABORATORY METHOD; POLLUTION EXPOSURE; PUBLIC HEALTH; TEMPORAL ANALYSIS; TOXICOLOGY;

ADENOSINE DIPHOSPHATE RIBOSYLATION; AIR POLLUTION; APOPTOSIS; ARTICLE; BIOSENSOR; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; LONG INTERSPERSED REPEAT; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SUMOYLATION; TISSUE SPECIFICITY;

DNA METHYLATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; GENETIC VARIATION; HISTONES; HUMANS; MICRORNAS;

EID: 84863338135     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyr154     Document Type: Article

References (385)

1. Prüss-Üstün Annette CC. Preventing disease through healthy environments. Towards an estimate of the environmental burden of disease World Health Organization (WHO), 2006.
2. Bollati V, Baccarelli A. Environmental epigenetics. Heredity 2010;105:105-12.
3. Bezek S, Ujhazy E, Mach M, Navarova J, Dubovicky M. Developmental origin of chronic diseases: toxicological implication. Interdiscip Toxicol 2008;1:29-31.
4. Tang WY, Ho SM. Epigenetic reprogramming and imprinting in origins of disease. Rev Endocr Metab Disord 2007;8:173-82.
5. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 2008;659:40-48.
6. Grewal SI, Moazed D. Heterochromatin and epigenetic control of gene expression. Science 2003;301: 798-802.
7. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science 2001;293: 1089-93.
8. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. Curr Opin Pediatr 2009;21:243-51.
9. Heightman TD. Therapeutic prospects for epigenetic modulation. Expert Opin Ther Targets 2011;15:729-40.
10. Wright RJ. Epidemiology of stress and asthma: from constricting communities and fragile families to epigenetics. Immunol Allergy Clin North Am 2011;31:19-39.
11. Miller OJ, Schnedl W, Allen J, Erlanger BF. 5-Methylcytosine localised in mammalian constitutive heterochromatin. Nature 1974;251:636-37.
12. Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 1997; 13:335-40.
13. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
14. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
15. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998;395:89-93.
16. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455.
17. Gaudet F, Hodgson JG, Eden A et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300: 489-92.
18. Laird PW. Cancer epigenetics. Hum Mol Genet 2005; (Spec No 1):R65-76.
19. Houck CM, Rinehart FP, Schmid CW. A ubiquitous family of repeated DNA sequences in the human genome. J Mol Biol 1979;132:289-306.
20. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:e38.
21. Weisenberger DJ, Campan M, Long TI et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005;33:6823-36.
22. Zhu ZZ, Hou L, Bollati V et al. Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis. Int J Epidemiol 2012;41:126-39.
23. Choi JY, James SR, Link PA et al. Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis 2009;30:1889-97.
24. Gronniger E, Weber B, Heil O et al. Aging and chronic sun exposure cause distinct epigenetic changes in human skin. PLoS Genet 2010;6:e1000971.
25. Deshmukh RS, Ostrup O, Ostrup E et al. DNA methylation in porcine preimplantation embryos developed in vivo and produced by in vitro fertilization, parthenogenetic activation and somatic cell nuclear transfer. Epigenetics 2011;6:177-87.
26. Anier K, Malinovskaja K, Aonurm-Helm A, Zharkovsky A, Kalda A. DNA methylation regulates cocaine-induced behavioral sensitization in mice. Neuropsychopharmacology 2010;35:2450-61.
27. Orta ML, Dominguez I, Pastor N, Cortes F, Mateos S. The role of the DNA hypermethylating agent Budesonide in the decatenating activity of DNA topoisomerase II. Mutat Res 2010;694:45-52.
28. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41:178-86.
29. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007;76:75-100.
30. Suganuma T, Workman JL. Crosstalk among Histone Modifications. Cell 2008;135:604-07.
31. Zheng YG, Wu J, Chen Z, Goodman M. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med Res Rev 2008;28:645-87.
32. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
33. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389:251-60.
34. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-32.
35. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000; 64:435-59.
36. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16.
37. Wang Z, Zang C, Rosenfeld JA et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008;40:897-903.
38. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 2007;8:307-18.
39. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005;6:838-49.
40. Wysocka J, Allis CD, Coonrod S. Histone arginine methylation and its dynamic regulation. Front Biosci 2006;11: 344-55.
41. Meissner A, Mikkelsen TS, Gu H et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008;454:766-70.
42. Singh SK, Pal Bhadra M, Girschick HJ, Bhadra U. MicroRNAs-micro in size but macro in function. FEBS J 2008;275:4929-44.
43. Matkovich SJ, Van Booven DJ, Eschenbacher WH, Dorn GW 2nd. RISC RNA sequencing for context-specific identification of in vivo microrna targets. Circ Res 2010; 108:18-26.
44. Williams AE. Functional aspects of animal microRNAs. Cell Mol Life Sci 2008;65:545-62.
45. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions of microRNAs: a review. J Physiol Biochem 2011;67:129-39.
46. Ying SY, Chang DC, Lin SL. The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol 2008;38:257-68.
47. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004;5:396-400.
48. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009; 41:87-95.
49. Backes C, Meese E, Lenhof HP, Keller A. A dictionary on microRNAs and their putative target pathways. Nucleic Acids Res 2010;38:4476-86.
50. Ho L, Fivecoat H, Wang J, Pasinetti GM. Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp Gerontol 2010;45:15-22.
51. Provost P. Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases. Aging 2010;2:166-69.
52. Provost P. MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases. Brain Res 2010;1338:58-66.
53. Cheng Y, Zhang C. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res 2010;3:251-55.
54. Montgomery RL, van Rooij E. MicroRNA regulation as a therapeutic strategy for cardiovascular disease. Curr Drug Targets 2010;11:936-42.
55. Shen E, Diao X, Wei C, Wu Z, Zhang L, Hu B. MicroRNAs target gene and signaling pathway by bioinformatics analysis in the cardiac hypertrophy. Biochem Biophys Res Commun 2010;397:380-85.
56. Swynghedauw B, Delcayre C, Samuel JL, Mebazaa A, Cohen-Solal A. Molecular mechanisms in evolutionary cardiology failure. Ann N Y Acad Sci 2010;1188:58-67.
57. Fabbri M, Croce CM, Calin GA. MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk Lymphoma 2009;50:160-70.
58. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008;15:352-58.
59. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010;42:1348-54.
60. Marcucci G, Radmacher MD, Mrozek K, Bloomfield CD. MicroRNA expression in acute myeloid leukemia. Curr Hematol Malig Rep 2009;4:83-88.
61. Motyckova G, Stone RM. The role of molecular tests in acute myelogenous leukemia treatment decisions. Curr Hematol Malig Rep 2010;5:109-17.
62. Zhao H, Wang D, Du W, Gu D, Yang R. MicroRNA and leukemia: tiny molecule, great function. Crit Rev Oncol Hematol 2010;74:149-55.
63. Chen J, Xu X. Diet, epigenetic, and cancer prevention. Adv Genet 2010;71:237-55.
64. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89.
65. Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. Br J Cancer 2010;103:1144-48.
66. Mathers JC, Strathdee G, Relton CL. Induction of epigenetic alterations by dietary and other environmental factors. Adv Genet 2010;71:3-39.
67. Howard Hu. Human health and heavy metals exposure. In: McCally M (ed.). Life Support: The Environment and Human Health. Boston: Massachusetts Institute of Technology, 2002.
68. Hemdan NY, Emmrich F, Faber S, Lehmann J, Sack U. Alterations of TH1/TH2 reactivity by heavy metals: possible consequences include induction of autoimmune diseases. Ann NY Acad Sci 2007;1109:129-37.
69. Waalkes MP. Cadmium carcinogenesis. Mutat Res 2003; 533:107-20.
70. Salnikow K, Zhitkovich A. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem Res Toxicol 2008;21: 28-44.
71. Huang C, Ke Q, Costa M, Shi X. Molecular mechanisms of arsenic carcinogenesis. Mol Cell Biochem 2004;255: 57-66.
72. Galaris D, Evangelou A. The role of oxidative stress in mechanisms of metal-induced carcinogenesis. Crit Rev Oncol Hematol 2002;42:93-103.
73. Leonard SS, Bower JJ, Shi X. Metal-induced toxicity, carcinogenesis, mechanisms and cellular responses. Mol Cell Biochem 2004;255:3-10.
74. Monks TJ, Xie R, Tikoo K, Lau SS. Ros-induced histone modifications and their role in cell survival and cell death. Drug Metab Rev 2006;38:755-67.
75. Donaldson K, Stone V, Borm PJ et al. Oxidative stress and calcium signaling in the adverse effects of environmental particles (PM10). Free Radic Biol Med 2003;34: 1369-82.
76. Gilmour PS, Rahman I, Donaldson K, MacNee W. Histone acetylation regulates epithelial IL-8 release mediated by oxidative stress from environmental particles. Am J Physiol Lung Cell Mol Physiol 2003;284:L533-40.
77. Babar IA, Slack FJ, Weidhaas JB. miRNA modulation of the cellular stress response. Future Oncol 2008;4:289-98.
78. Sakano K, Inagaki Y, Oikawa S, Hiraku Y, Kawanishi S. Copper-mediated oxidative DNA damage induced by eugenol: possible involvement of O-demethylation. Mutat Res 2004;565:35-44.
79. Galaris D, Skiada V, Barbouti A. Redox signaling and cancer: the role of "labile" iron. Cancer Lett 2008;266: 21-29.
80. Reichard JF, Schnekenburger M, Puga A. Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem Biophys Res Commun 2007;352:188-92.
81. Benbrahim-Tallaa L, Waterland RA, Styblo M, Achanzar WE, Webber MM, Waalkes MP. Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol 2005;206:288-98.
82. Coppin JF, Qu W, Waalkes MP. Interplay between cellular methyl metabolism and adaptive efflux during oncogenic transformation from chronic arsenic exposure in human cells. J Biol Chem 2008;283:19342-50.
83. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997;94: 10907-12.
84. Chen H, Li S, Liu J, Diwan BA, Barrett JC, Waalkes MP. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 2004;25: 1779-86.
85. Okoji RS, Yu RC, Maronpot RR, Froines JR. Sodium arsenite administration via drinking water increases genome-wide and Ha-ras DNA hypomethylation in methyl-deficient C57BL/6J mice. Carcinogenesis 2002;23: 777-85.
86. Uthus EO, Davis C. Dietary arsenic affects dimethylhydrazine-induced aberrant crypt formation and hepatic global DNA methylation and DNA methyltransferase activity in rats. Biol Trace Elem Res 2005;103: 133-45.
87. Xie Y, Trouba KJ, Liu J, Waalkes MP, Germolec DR. Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.AC) mice. Environ Health Perspect 2004;112:1255-63.
88. Majumdar S, Chanda S, Ganguli B, Mazumder DN, Lahiri S, Dasgupta UB. Arsenic exposure induces genomic hypermethylation. Environ Toxicol 2010;25:315-18.
89. Pilsner JR, Liu X, Ahsan H et al. Genomic methylation of peripheral blood leukocyte DNA: influences of arsenic and folate in Bangladeshi adults. Am J Clin Nutr 2007; 86:1179-86.
90. Chai CY, Huang YC, Hung WC, Kang WY, Chen WT. Arsenic salts induced autophagic cell death and hypermethylation of DAPK promoter in SV-40 immortalized human uroepithelial cells. Toxicol Lett 2007;173:48-56.
91. Fu HY, Shen JZ. Hypermethylation of CpG island of p16 gene and arsenic trioxide induced p16 gene demethylation in multiple myeloma. Zhonghua Nei Ke Za Zhi 2005; 44:411-14.
92. Jensen TJ, Novak P, Eblin KE, Gandolfi AJ, Futscher BW. Epigenetic remodeling during arsenical-induced malignant transformation. Carcinogenesis 2008;29:1500-508.
93. Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 1997;386:263-77.
94. Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol Appl Pharmacol 2001;175: 260-68.
95. Takahashi M, Barrett JC, Tsutsui T. Transformation by inorganic arsenic compounds of normal Syrian hamster embryo cells into a neoplastic state in which they become anchorage-independent and cause tumors in newborn hamsters. Int J Cancer 2002;99:629-34.
96. Cui X, Wakai T, Shirai Y, Hatakeyama K, Hirano S. Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicol Sci 2006; 91:372-81.
97. Waalkes MP, Liu J, Chen H et al. Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. J Natl Cancer Inst 2004;96:466-74.
98. Chanda S, Dasgupta UB, Guhamazumder D et al. DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol Sci 2006;89:431-37.
99. Chen WT, Hung WC, Kang WY, Huang YC, Chai CY. Urothelial carcinomas arising in arsenic-contaminated areas are associated with hypermethylation of the gene promoter of the death-associated protein kinase. Histopathology 2007;51:785-92.
100. Marsit CJ, Karagas MR, Danaee H et al. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 2006;27:112-16.
101. Zhang AH, Bin HH, Pan XL, Xi XG. Analysis of p16 gene mutation, deletion and methylation in patients with arseniasis produced by indoor unventilated-stove coal usage in Guizhou, China. J Toxicol Environ Health A 2007;70:970-75.
102. Boonchai W, Walsh M, Cummings M, Chenevix-Trench G. Expression of p53 in arsenic-related and sporadic basal cell carcinoma. Arch Dermatol 2000;136: 195-98.
103. Arrigo AP. Acetylation and methylation patterns of core histones are modified after heat or arsenite treatment of Drosophila tissue culture cells. Nucleic Acids Res 1983;11: 1389-404.
104. Jo WJ, Ren X, Chu F et al. Acetylated H4K16 by MYST1 protects UROtsa cells from arsenic toxicity and is decreased following chronic arsenic exposure. Toxicol Appl Pharmacol 2009;241:294-302.
105. Li J, Chen P, Sinogeeva N et al. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem 2002;277:49504-10.
106. Li J, Gorospe M, Barnes J, Liu Y. Tumor promoter arsenite stimulates histone H3 phosphoacetylation of proto-oncogenes c-fos and c-jun chromatin in human diploid fibroblasts. J Biol Chem 2003;278: 13183-91.
107. Ramirez T, Brocher J, Stopper H, Hock R. Sodium arsenite modulates histone acetylation, histone deacetylase activity and HMGN protein dynamics in human cells. Chromosoma 2008;117:147-57.
108. Desrosiers R, Tanguay RM. Further characterization of the posttranslational modifications of core histones in response to heat and arsenite stress in Drosophila. Biochem Cell Biol 1986;64:750-57.
109. Desrosiers R, Tanguay RM. Methylation of Drosophila histones at proline, lysine, and arginine residues during heat shock. J Biol Chem 1988;263:4686-92.
110. Zhou X, Sun H, Ellen TP, Chen H, Costa M. Arsenite alters global histone H3 methylation. Carcinogenesis 2008;29:1831-36.
111. Zhou X, Li Q, Arita A, Sun H, Costa M. Effects of nickel, chromate, and arsenite on histone 3 lysine methylation. Toxicol Appl Pharmacol 2009;236:78-84.
112. Zykova TA, Zhu F, Lu C et al. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. Clin Cancer Res 2006;12: 6884-93.
113. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res 2006;66:10843-48.
114. Binet F, Antoine F, Girard D. Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin. Inflamm Allergy Drug Targets 2009;8:21-27.
115. Cao Y, Yu SL, Wang Y, Guo GY, Ding Q, An RH. MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. Tumour Biol 2011;32:179-88.
116. Lee YW, Klein CB, Kargacin B et al. Carcinogenic nickel silences gene-expression by chromatin condensation and DNA methylation - a new model for epigenetic carcinogens. Mol Cell Biol 1995;15:2547-57.
117. Lee YW, Klein CB, Kargacin B et al. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol Cell Biol 1995;15:2547-57.
118. Klein CB, Conway K, Wang XW et al. Senescence of nickel-transformed cells by an X chromosome: possible epigenetic control. Science 1991;251:796-99.
119. Govindarajan B, Klafter R, Miller MS et al. Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol Med 2002;8:1-8.
120. Karaczyn AA, Golebiowski F, Kasprzak KS. Truncation, deamidation, and oxidation of histone H2B in cells cultured with nickel(II). Chem Res Toxicol 2005;18: 1934-42.
121. Karaczyn A, Ivanov S, Reynolds M, Zhitkovich A, Kasprzak KS, Salnikow K. Ascorbate depletion mediates up-regulation of hypoxia-associated proteins by cell density and nickel. J Cell Biochem 2006;97:1025-35.
122. Broday L, Peng W, Kuo MH, Salnikov K, Zoroddu M, Costa M. Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res 2000;60:238-41.
123. Chen H, Ke Q, Kluz T, Yan Y, Costa M. Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing. Mol Cell Biol 2006;26:3728-37.
124. Ke QD, Davidson T, Chen HB, Kluz T, Costa M. Alterations of histone modifications and transgene silencing by nickel chloride. Carcinogenesis 2006;27:1481-88.
125. Golebiowski F, Kasprzak KS. Inhibition of core histones acetylation by carcinogenic nickel(II). Mol Cell Biochem 2005;279:133-39.
126. Klein CB, Costa M. DNA methylation, heterochromatin and epigenetic carcinogens. Mutat Res-Rev Mutat Res 1997; 386:163-80.
127. Klein CB, Conway K, Wang XW et al. Senescence of nickel-transformed cells by an x-chromosome - possible epigenetic control. Science 1991;251:796-99.
128. Yan Y, Kluz T, Zhang P, Chen HB, Costa M. Analysis of specific lysine histone H3 and H4 acetylation and methylation status in clones of cells with a gene silenced by nickel exposure. Toxicol Appl Pharmacol 2003;190:272-77.
129. Zhang QW, Salnikow K, Kluz T, Chen LC, Su WC, Costa M. Inhibition and reversal of nickel-induced transformation by the histone deacetylase inhibitor trichostatin A. Toxicol Appl Pharmacol 2003;192:201-11.
130. Broday L, Peng W, Kuo MH, Salnikow K, Zoroddu M, Costa M. Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res 2000;60:238-41.
131. Golebiowski F, Kasprzak KS. Inhibition of core histones acetylation by carcinogenic nickel(II). Mol Cell Biochem 2005;279:133-39.
132. Ke Q, Li Q, Ellen TP, Sun H, Costa M. Nickel compounds induce phosphorylation of histone H3 at serine 10 by activating JNK-MAPK pathway. Carcinogenesis 2008;29: 1276-81.
133. Huang D, Zhang Y, Qi Y, Chen C, Ji W. Global DNA hypomethylation, rather than reactive oxygen species (ROS), a potential facilitator of cadmium-stimulated K562 cell proliferation. Toxicol Lett 2008;179:43-47.
134. Takiguchi M, Achanzar WE, Qu W, Li G, Waalkes MP. Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. Exp Cell Res 2003;286:355-65.
135. Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, Guallar E. Cadmium exposure and hypertension in the 1999-2004 National Health and Nutrition Examination Survey (NHANES). Environ Health Perspect 2008;116: 51-56.
136. Bhatnagar A. Environmental cardiology - Studying mechanistic links between pollution and heart disease. Circulation Res 2006;99:692-705.
137. Bollati V, Marinelli B, Apostoli P et al. Exposure to metal-rich particulate matter modifies the expression of candidate microRNAs in peripheral blood leukocytes. Environ Health Perspect 2010;118:763-68.
138. Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans 2008;36(Pt 6):1211-15.
139. Pilsner JR, Lazarus AL, Nam DH et al. Mercury-associated DNA hypomethylation in polar bear brains via the LUminometric Methylation Assay: a sensitive method to study epigenetics in wildlife. Mol Ecol 2010;19:307-14.
140. Arai Y, Ohgane J, Yagi S et al. Epigenetic Assessment of environmental chemicals detected in maternal peripheral and cord blood samples. J Reprod Dev 2011;57:507-17.
141. Wright RO, Schwartz J, Wright RJ et al. Biomarkers of lead exposure and DNA methylation within retrotransposons. Environ Health Perspect 2010;118:790-95.
142. Pilsner JR, Hu H, Ettinger A et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. Environ Health Perspect 2009;117:1466-71.
143. Kondo K, Takahashi Y, Hirose Y et al. The reduced expression and aberrant methylation of p16(INK4a) in chromate workers with lung cancer. Lung Cancer 2006; 53:295-302.
144. Takahashi Y, Kondo K, Hirose T et al. Microsatellite instability and protein expression of the DNA mismatch repair gene, hMLH1, of lung cancer in chromate-exposed workers. Mol Carcinogenesis 2005;42:150-58.
145. Frouin H, Fortier M, Fournier M. Toxic effects of various pollutants in 11B7501 lymphoma B cell line from harbour seal (Phoca vitulina). Toxicology 2010;270:66-76.
146. Apostoli P, Catalani S. Mechanisms of action for metallic elements and their species classified carcinogen R 45 and R 49 by EU. G Ital Med Lav Ergon 2008;30:382-91.
147. Schnekenburger M, Talaska G, Puga A. Chromium cross-links histone deacetylase 1-DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation. Mol Cell Biol 2007;27:7089-101.
148. Sun H, Zhou X, Chen H, Li Q, Costa M. Modulation of histone methylation and MLH1 gene silencing by hexavalent chromium. Toxicol Appl Pharmacol 2009;237: 258-66.
149. Pogue AI, Li YY, Cui JG et al. Characterization of an NF-kappaB-regulated, miRNA-146a-mediated downregulation of complement factor H (CFH) in metalsulfate-stressed human brain cells. J Inorg Biochem 2009;103:1591-95.
150. Lukiw WJ, Pogue AI. Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. J Inorg Biochem 2007;101: 1265-69.
151. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
152. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010;29: 181-206.
153. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
154. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005;308:1466-69.
155. Guerrero-Bosagna C, Settles M, Lucker B, Skinner MK. Epigenetic transgenerational actions of vinclozolin on promoter regions of the sperm epigenome. PLoS One 2010;5:e13100.
156. Anway MD, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors. Endocrinology 2006; 147(6 Suppl):S43-49.
157. Zama AM, Uzumcu M. Fetal and neonatal exposure to the endocrine disruptor methoxychlor causes epigenetic alterations in adult ovarian genes. Endocrinology 2009; 150:4681-91.
158. Tao L, Yang S, Xie M, Kramer PM, Pereira MA. Hypomethylation and overexpression of c-jun and c-myc protooncogenes and increased DNA methyltransferase activity in dichloroacetic and trichloroacetic acidpromoted mouse liver tumors. Cancer Lett 2000;158: 185-93.
159. Tao L, Yang S, Xie M, Kramer PM, Pereira MA. Effect of trichloroethylene and its metabolites, dichloroacetic acid and trichloroacetic acid, on the methylation and expression of c-Jun and c-Myc protooncogenes in mouse liver: prevention by methionine. Toxicol Sci 2000;54:399-407.
160. Hathaway G, Proctor N, Hughes J, Fischman M. Proctor And Hughes' Chemical Hazards of the Workplace. New York: Van Nostrand Reinhold, 1991.
161. Rusiecki JA, Baccarelli A, Bollati V, Tarantini L, Moore LE, Bonefeld-Jorgensen EC. Global DNA hypomethylation is associated with high serum-persistent organic pollutants in Greenlandic Inuit. Environ Health Perspect 2008;116:1547-52.
162. Kim KY, Kim DS, Lee SK et al. Association of low-dose exposure to persistent organic pollutants with global DNA hypomethylation in healthy koreans. Environ Health Perspect 2010;118:370-74.
163. Alavanja MC, Bonner MR. Pesticides and human cancers. Cancer Invest 2005;23:700-11.
164. Weichenthal S, Moase C, Chan P. A review of pesticide exposure and cancer incidence in the Agricultural Health Study cohort. Environ Health Perspect 2010;118: 1117-25.
165. Alavanja MC, Ward MH, Reynolds P. Carcinogenicity of agricultural pesticides in adults and children. J Agromedicine 2007;12:39-56.
166. Bassil KL, Vakil C, Sanborn M, Cole DC, Kaur JS, Kerr KJ. Cancer health effects of pesticides: systematic review. Can Fam Physician 2007;53:1704-11.
167. Koutros S, Alavanja MC, Lubin JH et al. An update of cancer incidence in the Agricultural Health Study. J Occup Environ Med 2010;52:1098-105.
168. Waggoner JK, Kullman GJ, Henneberger PK et al. Mortality in the agricultural health study, 1993-2007. Am J Epidemiol 2011;173:71-83.
169. Song C, Kanthasamy A, Anantharam V, Sun F, Kanthasamy AG. Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol Pharmacol 2010; 77:621-32.
170. Song C, Kanthasamy A, Anantharam V, Sun F, Kanthasamy AG. Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol Pharmacol 2010; 77:621-32.
171. Baccarelli A, Cassano PA, Litonjua A et al. Cardiac autonomic dysfunction - effects from particulate air pollution and protection by dietary methyl nutrients and metabolic polymorphisms. Circulation 2008;117: 1802-09.
172. Jardim MJ, Fry RC, Jaspers I, Dailey L, Diaz-Sanchez D. Disruption of microRNA expression in human airway cells by diesel exhaust particles is linked to tumorigenesis-associated pathways. Environ Health Perspect 2009;117:1745-51.
173. Tarantini L, Bonzini M, Apostoli P et al. Effects of particulate matter on genomic DNA methylation content and iNOS promoter methylation. Environ Health Perspect 2009;117:217-22.
174. Yauk C, Polyzos A, Rowan-Carroll A et al. Germ-line mutations, DNA damage, and global hypermethylation in mice exposed to particulate air pollution in an urban/industrial location. Proc Natl Acad Sci USA 2008;105: 605-10.
175. Liu J, Ballaney M, Al-alem U et al. Combined inhaled diesel exhaust particles and allergen exposure alter methylation of T helper genes and IgE production in vivo. Toxicol Sci 2008;102:76-81.
176. Perera F, Tang WY, Herbstman J et al. Relation of DNA methylation of 5′-CpG island of ACSL3 to transplacental exposure to airborne polycyclic aromatic hydrocarbons and childhood asthma. PLoS One 2009;4:e4488.
177. Cantone L, Nordio F, Hou L et al. Effects of Inhalable Metal-rich Air Particles on Histone H3K4 Dimethylation and H3K9 Acetylation in a Cross-sectional Study of Steel Workers. Environ Health Perspect 2011;119:964-9.
178. Bollati V, Marinelli B, Apostoli P et al. Exposure to metal-rich particulate matter modifies the expression of candidate micrornas in peripheral blood leukocytes. Environ Health Perspect 2010.
179. Smith MT. Advances in understanding benzene health effects and susceptibility. Annu Rev Public Health 2010; 31:133-48 2 p following 148.
180. Rinsky RA, Hornung RW, Silver SR, Tseng CY. Benzene exposure and hematopoietic mortality: a long-term epidemiologic risk assessment. Am J Ind Med 2002;42: 474-80.
181. Goldstein BD. Benzene toxicity. Occup Med 1988;3: 541-54.
182. Whitworth KW, Symanski E, Coker AL. Childhood lymphohematopoietic cancer incidence and hazardous air pollutants in southeast Texas, 1995-2004. Environ Health Perspect 2008;116:1576-80.
183. Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl 1987;7:1-440.
184. Richardson DB. Temporal variation in the association between benzene and leukemia mortality. Environ Health Perspect 2008;116:370-74.
185. CDC. Facts About Benzene. 2005. Available from: http://www.bt.cdc.gov/agent/benzene/basics/facts.asp.
186. Bollati V, Baccarelli A, Hou L et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res 2007;67:876-80.
187. Ji Z, Zhang L, Peng V, Ren X, McHale CM, Smith MT. A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide. Leukemia 2010;24:986-91.
188. Gao A, Zuo X, Liu Q, Lu X, Guo W, Tian L. Methylation of PARP-1 promoter involved in the regulation of benzene-induced decrease of PARP-1 mRNA expression. Toxicol Lett 2010;195:114-18.
189. Keri RA, Ho SM, Hunt PA, Knudsen KE, Soto AM, Prins GS. An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol 2007;24: 240-52.
190. Ho SM, Tang WY, de Frausto JB, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 2006;66:5624-32.
191. vom Saal FS, Hughes C. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. Environ Health Perspect 2005;113:926-33.
192. Dolinoy DC, Huang D, Jirtle RL. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc Natl Acad Sci USA 2007;104:13056-61.
193. Waterland RA. Is epigenetics an important link between early life events and adult disease? Horm Res 2009; 71(Suppl 1):13-16.
194. Bromer JG, Zhou Y, Taylor MB, Doherty L, Taylor HS. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. FASEB J 2010;24:2273-80.
195. Weng YI, Hsu PY, Liyanarachchi S et al. Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicol Appl Pharmacol 2010;248: 111-21.
196. Avissar-Whiting M, Veiga KR, Uhl KM et al. Bisphenol A exposure leads to specific microRNA alterations in placental cells. Reprod Toxicol 2010;29:401-06.
197. Beedanagari SR, Taylor RT, Bui P, Wang F, Nickerson DW, Hankinson O. Role of epigenetic mechanisms in differential regulation of the dioxin-inducible human CYP1A1 and CYP1B1 genes. Mol Pharmacol 2010; 78:608-16.
198. Wang J, Zhao YY, Liu H et al. The role of insulin-like growth factor-2 gene differentially methylated regions in TCDD-induced malformation. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2007;24:162-66.
199. McClure EA, North CM, Kaminski NE, Goodman JI. Changes in DNA methylation and gene expression during 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced suppression of the lipopolysaccharide (LPS)-stimulated IgM response in splenocytes. Toxicol Sci 2011;120:339-48.
200. Elyakim E, Sitbon E, Faerman A et al. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res 2010;70:8077-87.
201. Beller HR, Tiemeier K. Use of liquid chromatography/tandem mass spectrometry to detect distinctive indicators of in situ RDX transformation in contaminated groundwater. Environ Sci Techno 2002;36:2060-66.
202. Zhang B, Pan X. RDX induces aberrant expression of microRNAs in mouse brain and liver. Environ Health Perspect 2009;117:231-40.
203. Laitman CJ. DES exposure and the aging woman: mothers and daughters. Curr Womens Health Rep 2002;2: 390-93.
204. Palmer JR, Hatch EE, Rosenberg CL et al. Risk of breast cancer in women exposed to diethylstilbestrol in utero: prelimiinary results (United States). Cancer Causes Control 2002;13:753-58.
205. Hsu PY, Deatherage DE, Rodriguez BA et al. Xenoestrogeninduced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res 2009;69:5936-45.
206. Mages F, Macovschi O, Prigent AF, Fonlupt P. Increased methylation of chloroform extractable products and CTP: cholinephosphate cytidylyltransferase in brain membrane preparations from triethyltin-intoxicated rats. Pharmacol Toxicol 1989;65:302-05.
207. Pereira MA, Kramer PM, Conran PB, Tao L. Effect of chloroform on dichloroacetic acid and trichloroacetic acid-induced hypomethylation and expression of the c-myc gene and on their promotion of liver and kidney tumors in mice. Carcinogenesis 2001;22:1511-19.
208. Coffin JC, Ge R, Yang S, Kramer PM, Tao L, Pereira MA. Effect of trihalomethanes on cell proliferation and DNA methylation in female B6C3F1 mouse liver. Toxicol Sci 2000;58:243-52.
209. Chlorinated drinking-water. IARC Monogr Eval Carcinog Risks Hum 1991;52:45-141.
210. Uden PC, Miller JW. Chlorinated acids and chloral in drinking water. J Am Water Works Assoc 1983;75:524-27.
211. Coleman WE, Munch JW, Kaylor WH, Streicher RP, Ringhand HP, Meier JR. Gas chromatography/mass spectroscopy analysis of mutagenic extracts of aqueous chlorinated humic acid. A comparison of the by-products to drinking water contaminants Environ. Sci. Technol. 1984;18:674-78.
212. Shi L, Wu J. Epigenetic regulation in mammalian preimplantation embryo development. Reprod Biol Endocrinol 2009;7:59-69.
213. Morgan HD, Sutherland HG, Martin DI, Whitelaw E. Epigenetic inheritance at the agouti locus in the mouse. Nat Genet 1999;23:314-18.
214. Heijmans BT, Tobi EW, Stein AD et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA 2008;105: 17046-49.
215. Tobi EW, Lumey LH, Talens RP et al. DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. Hum Mol Genet 2009;18:4046-53.
216. Heijmans BT, Tobi EW, Lumey LH, Slagboom PE. The epigenome: archive of the prenatal environment. Epigenetics 2009;4:526-31.
217. Terry MB, Ferris JS, Pilsner R et al. Genomic DNA methylation among women in a multiethnic New York City birth cohort. Cancer Epidemiol Biomarkers Prev 2008; 17:2306-10.
218. Flom J, Ferris J, Gonzalez K, Santella R, Terry M. Prenatal tobacco smoke exposure and genomewide methylation in adulthood. Cancer Epidemiol Biomarkers Prev 2011;20:720-21.
219. Guerrero-Preston R, Goldman LR, Brebi-Mieville P et al. Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics 2010;5:539-46.
220. Maccani MA, Avissar-Whiting M, Banister CE, McGonnigal B, Padbury JF, Marsit CJ. Maternal cigarette smoking during pregnancy is associated with downregulation of miR-16, miR-21, and miR-146a in the placenta. Epigenetics 2010;5:583-89.
221. Minard ME, Jain AK, Barton MC. Analysis of epigenetic alterations to chromatin during development. Genesis 2009;47:559-72.
222. Relton CL, Davey Smith G. Epigenetic epidemiology of common complex disease: prospects for prediction, prevention, and treatment. PLoS Med 2010;7:e1000356.
223. Geneletti S, Gallo V, Porta M, Khoury MJ, Vineis P. Assessing causal relationships in genomics: From Bradford-Hill criteria to complex gene-environment interactions and directed acyclic graphs. Emerg Themes Epidemiol 2011;8:5-22.
224. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005; 15:490-95.
225. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007;61(5 Pt 2):24R-29R.
226. Sciandrello G, Caradonna F, Mauro M, Barbata G. Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells. Carcinogenesis 2004; 25:413-17.
227. Smith IM, Mydlarz WK, Mithani SK, Califano JA. DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer 2007;121:1724-28.
228. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 2006;20:1445-48.
229. Deng G, Nguyen A, Tanaka H et al. Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int J Cancer 2006;118: 2999-3005.
230. Brothman AR, Swanson G, Maxwell TM et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 2005;156:31-36.
231. Shimabukuro M, Sasaki T, Imamura A et al. Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. J Psychiatr Res 2007;41: 1042-46.
232. Bagnyukova TV, Luzhna LI, Pogribny IP, Lushchak VI. Oxidative stress and antioxidant defenses in goldfish liver in response to short-term exposure to arsenite. Environ Mol Mutagen 2007;48:658-65.
233. Pilsner JR, Liu X, Ahsan H et al. Folate deficiency, hyperhomocysteinemia, low urinary creatinine, and hypomethylation of leukocyte DNA are risk factors for arsenic-induced skin lesions. Environ Health Perspect 2009;117:254-60.
234. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-20 deoxycytidine to increase SPARC expression and improve therapy response. British J Cancer 2008;98:1810-19.
235. Alemayehu A, Sebova K, Fridrichova I. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients. Genes Chrom Cancer 2008;47:906-14.
236. Norrie MWA, Hawkins NJ, Todd AV, Meagher AP, O'Connor TW, Ward RL. The role of hMLH1 methylation in the development of synchronous sporadic colorectal carcinomas. Dis Colon Rectum 2002;45:674-80.
237. Minardi D, Lucarini G, Filosa A et al. Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. J Cell Mol Med 2009;13:2115-21.
238. Schafer E, Irizarry R, Negi S et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood 2010;115: 4798-809.
239. Owen HC, Giedl J, Wild PJ et al. Low frequency of epigenetic events in urothelial tumors in young patients. J Urol 2010;184:459-63.
240. Qian J, Yao DM, Lin J et al. Alteration of methylation status of death-associated protein kinase (dapk) gene promoter in patients with acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010;18: 1390-94.
241. Laytragoon-Lewin N, Chen F, Castro J et al. DNA content and methylation of p16, DAPK and RASSF1A gene in tumour and distant, normal mucosal tissue of head and neck squamous cell carcinoma patients. Anticancer Res 2010;30:4643-48.
242. Paluszczak J, Misiak P, Wierzbicka M, Wozniak A, Baer-Dubowska W. Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. Oral Oncol 2011;47:104-7.
243. Hafner N, Diebolder H, Jansen L, Hoppe I, Durst M, Runnebaum IB. Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer. Gynecol Oncol 2011;121:224-9.
244. Li B, Wang B, Niu LJ, Jiang L, Qiu CC. Hypermethylation of multiple tumor-related genes associated with DMNT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics 2011;6:307-16.
245. Ben Ayed-Guerfali D, Benhaj K, Khabir A et al. Hypermethylation of tumor-related genes in tunisian patients with gastric carcinoma: Clinical and biological significance. J Surg Oncol 2011;103:687-94.
246. Sugita H, Iida S, Inokuchi M et al. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep 2011; 25:513-18.
247. Zhang Y, Wang R, Song H et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011;303:21-8.
248. Hu SL, Kong XY, Cheng ZD et al. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Tumori 2010;96:726-33.
249. Van der Auwera I, Bovie C, Svensson C et al. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer 2010;10:97-104.
250. Zhang C, Jin Y, Xu H et al. Relationship between promoter methylation of p16, DAPK and RAR beta genes and the clinical data of non-small cell lung cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011;28:23-28.
251. Peng Z, Shan C, Wang H. Value of promoter methylation of RASSF1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35:247-53.
252. Malhotra P, Kochhar R, Vaiphei K, Wig JD, Mahmood S. Aberrant promoter methylation of p16 in colorectal adenocarcinoma in North Indian patients. World J Gastrointest Oncol 2010;2:295-303.
253. Poetsch M, Hemmerich M, Kakies C et al. Alterations in the tumor suppressor gene p16 (INK4A) are associated with aggressive behavior of penile carcinomas. Virchows Arch 2011;458:221-29.
254. Lin HH, Ke HL, Wu WJ, Lee YH, Chang LL. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection. Urol Oncol 2010; in press.
255. Wang D, Wang J, Li Y, He Z, Zhang Y. The influence of anthracosis and p16 ink4a gene aberrant methylation on small-sized pulmonary adenocarcinoma. Exp Mol Pathol 2011;90:131-36.
256. Zainuddin N, Kanduri M, Berglund M et al. Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma. Leuk Res 2011;35:438-43.
257. Shaw R, Risk JM, Liloglou T. RE: P16 INK41 promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age dependent manner. Su et al. Oral Oncol 2010;46:734-39.
258. Serizawa RR, Ralfkiaer U, Steven K et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J Cancer 2011;129:78-87.
259. Hill VK, Hesson LB, Dansranjavin T et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 2010;9:51-63.
260. Gronbaek K, Ralfkiaer U, Dahl C et al. Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms. Mod Pathol 2008;21:632-38.
261. Radpour R, Barekati Z, Haghighi MM et al. Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod Pathol 2010;23:763-72.
262. Hanafusa T, Shinji T, Shiraha H et al. Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer 2005;5:9-19.
263. Luo J, Li YN, Wang F, Zhang WM, Geng X. S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int J Biol Sci 2010;6:784-95.
264. Fang JY, Zhu SS, Xiao SD et al. Studies on the hypomethylation of c-myc, c-Ha-ras oncogenes and histopathological changes in human gastric carcinoma. J Gastroenterol Hepatol 1996;11:1079-82.
265. Tsujiuchi T, Tsutsumi M, Sasaki Y, Takahama M, Konishi Y. Hypomethylation of CpG sites and c-myc gene overexpression in hepatocellular carcinomas, but not hyperplastic nodules, induced by a choline-deficient L-amino acid-defined diet in rats. Jpn J Cancer Res 1999; 90:909-13.
266. Shen L, Qui D, Fang J. Correlation between hypomethylation of c-myc and c-N-ras oncogenes and pathological changes in human hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 1997;19:173-76.
267. Del Senno L, Maestri I, Piva R et al. Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades. J Urol 1989;142: 146-49.
268. Rabiau N, Thiam MO, Satih S et al. Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo 2009;23:387-91.
269. Buckingham L, Penfield Faber L, Kim A et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 2010;126:1630-39.
270. Zhang A, Feng H, Yang G et al. Unventilated indoor coal-fired stoves in Guizhou province, China: cellular and genetic damage in villagers exposed to arsenic in food and air. Environ Health Perspect 2007;115:653-8.
271. Zhong CX, Mass MJ. Both hypomethylation and hypermethylation of DNA associated with arsenite exposure in cultures of human cells identified by methylationsensitive arbitrarily-primed PCR. Toxicol Lett 2001;122: 223-34.
272. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 2008;180:1131-36.
273. Jo WJ, Ren XF, Chu FX et al. Acetylated H4K16 by MYST1 protects UROtsa cells from arsenic toxicity and is decreased following chronic arsenic exposure. Toxicol Appl Pharmacol 2009;241:294-302.
274. Sayyed SG, Gaikwad AB, Lichtnekert J et al. Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10. Nephrol Dial Transplant 2010;25:1811-17.
275. Gaikwad AB, Sayyed SG, Lichtnekert J, Tikoo K, Anders HJ. Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes. Am J Pathol 2010;176:1079-83.
276. Gao WM, Chadha MS, Kline AE et al. Immunohistochemical analysis of histone H3 acetylation and methylation - evidence for altered epigenetic signaling following traumatic brain injury in immature rats. Brain Res 2006;1070:31-4.
277. Zhao F, Chen Y, Zeng L et al. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol 2010;646:1-11.
278. Seligson DB, Horvath S, McBrian MA et al. Global Levels of Histone Modifications Predict Prognosis in Different Cancers. Am J Pathol 2009;174:1619-28.
279. Arita A, Costa M. Epigenetics in metal carcinogenesis: Nickel, Arsenic, Chromium and Cadmium. Metallomics 2009;1:222-28.
280. Chen MW, Hua KT, Kao HJ et al. H3K9 Histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010;70:7830-40.
281. Yao JY, Zhang L, Zhang X et al. H3K27 trimethylation is an early epigenetic event of p16(INK4a) silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells. J Biol Chem 2010;285:18828-37.
282. Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 2010;115:3098-108.
283. Porcedda P, Turinetto V, Brusco A et al. A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry A 2008;73:508-16.
284. Barr FD, Krohmer LJ, Hamilton JW, Sheldon LA. Disruption of histone modification and CARM1 recruitment by arsenic represses transcription at glucocorticoid receptor-regulated promoters. PLoS One 2009;4:e6766.
285. Ashktorab H, Belgrave K, Hosseinkhah F et al. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Digestive Dis Sci 2009;54: 2109-17.
286. Felli N, Fontana L, Pelosi E et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005;102:18081-86.
287. le Sage C, Nagel R, Egan DA et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007;26: 3699-708.
288. Garofalo M, Di Leva G, Romano G et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509.
289. Mi SL, Lu J, Sun M et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Blood 2007;110:75a.
290. Saumet A, Vetter G, Bouttier M et al. Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood 2009;113:412-21.
291. Hebert SS, Horre K, Nicolai L et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 2008;105:6415-20.
292. Takakura S, Mitsutake N, Nakashima M et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 2008;99:1147-54.
293. Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004;101:11755-60.
294. Arndt GM, Dossey L, Cullen LM et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009;9:374-90.
295. Bandres E, Cubedo E, Agirre X et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006;5:29-38.
296. Malzkorn B, Wolter M, Grzendowski M, Stuhler K, Reifenberger G. Identification and functional characterization of microRNAs involved in the malignant progression of astrocytic gliomas. Brain Pathol 2010;20:539-50.
297. Hebert C, Norris K, Scheper MA, Nikitakis N, Sauk JJ. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007;6: 5-15.
298. Budhu A, Jia HL, Forgues M et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907.
299. Connolly E, Melegari M, Landgraf P et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008; 173:856-64.
300. Hayashita Y, Osada H, Tatematsu Y et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32.
301. Chim CS, Fung TK, Liang R. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 2003;17: 2533-35.
302. Stirzaker C, Millar DS, Paul CL et al. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res 1997;57:2229-37.
303. Chen MN, Mao Q, Liu YH, Mao BY. Methylation and expression analysis of p16(INK4a) and RB genes in meningiomas. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2004;21:277-79.
304. Zhao YF, Shen SP, Jiang JY, Geng H, Guo JG, Xie LP. Methylation and expression of gene p16INK4a and RB in breast carcinoma. Zhonghua Bing Li Xue Za Zhi 2010;39: 377-81.
305. Zhao Y, Tian X, Du J et al. Methylation and expression of gene p16INK4a and RB in gastric carcinomas. Beijing Da Xue Xue Bao 2003;35:382-85.
306. Li H, Lu S, Fong L. Study on the status of methylation of Rb gene promoter in human esophageal cancer and effect of NMBzA on Rb gene promoter in monkey esophageal epithelium. Zhonghua Zhong Liu Za Zhi 1998;20:412-14.
307. Ke Q, Davidson T, Chen H, Kluz T, Costa M. Alterations of histone modifications and transgene silencing by nickel chloride. Carcinogenesis 2006;27:1481-88.
308. Chen MW, Hua KT, Kao HJ et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010;70:7830-40.
309. Lefevre GM, Patel SR, Kim D, Tessarollo L, Dressler GR. Altering a histone H3K4 methylation pathway in glomerular podocytes promotes a chronic disease phenotype. PLoS Genet 2010;6:e1001142.
310. Kumar R, Hunt CR, Gupta A et al. Purkinje cell-specific males absent on the first (mMof) gene deletion results in an ataxia-telangiectasia-like neurological phenotype and backward walking in mice. Proc Natl Acad Sci USA 2011;108:3636-41.
311. Gramantieri L, Ferracin M, Fornari F et al. Cyclin g1 is a target of miR-122a, a MicroRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007;67:6092-99.
312. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 2008;105:7269-74.
313. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. Rna-a Publication of the RNA Society 2008;14:417-24.
314. Gonzalez-Ramirez I, Ramirez-Amador V, Irigoyen-Camacho ME et al. hMLH1 promoter methylation is an early event in oral cancer. Oral Oncol 2011;47:22-26.
315. Vasavi M, Kiran V, Ravishankar B, Prabhakar B, Ahuja YR, Hasan Q. Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers. Cancer Biomark 2010;7:1-10.
316. Ling ZQ, Tanaka A, Li P et al. Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma. Cancer Lett 2010;297:244-51.
317. Klein CB, Su L, Bowser D, Leszczynska J. Chromate-induced epimutations in mammalian cells. Environ Health Perspect 2002;110(Suppl 5):739-43.
318. Lukiw WJ, Zhao YH, Cui JG. An NF-kappa B-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008;283:31315-22.
319. Pogue AI, Li YY, Cui JG et al. Characterization of an NF-kappa B-regulated, miRNA-146a-mediated downregulation of complement factor H (CFH) in metalsulfate-stressed human brain cells. J Inorg Biochem 2009;103:1591-95.
320. Cheng YH, Ji RR, Yue JM et al. MicroRNAs are aberrantly expressed in hypertrophic heart - Do they play a role in cardiac hypertrophy? Am J Pathol 2007;170: 1831-40.
321. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61.
322. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappa B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103:12481-86.
323. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappa B activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008;27:5643-5647.
324. Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008;29:1963-66.
325. Calin GA, Ferracin M, Cimmino A et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New Engl J Med 2005;353: 1793-801.
326. Xu T, Zhu Y, Wei QK et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008;29:2126-31.
327. Yanaihara N, Caplen N, Bowman E et al. Unique MicroRNA molecular profiles in lung cancer diagnosis and prognosis. Toxicol Pathol 2006;34:1017-18.
328. Kozaki KI, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68:2094-105.
329. Lukiw WJ, Pogue AI. Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. J Inorg Biochem 2007;101: 1265-69.
330. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007;18: 297-300.
331. Saba R, Goodman CD, Huzarewich RLCH, Robertson C, Booth SA. A miRNA Signature of Prion Induced Neurodegeneration. PLos One 2008;3:e3652.
332. Roehle A, Hoefig KP, Repsilber D et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. British J Haematol 2008;142: 732-44.
333. Wang Y, Lee ATC, Ma JZI et al. Profiling MicroRNA expression in hepatocellular carcinoma reveals MicroRNA-224 up-regulation and apoptosis inhibitor-5 as a MicroRNA-224-specific target. J Biol Chem 2008; 283:13205-15.
334. Tan HX, Wang QA, Chen LZ et al. MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. Med Oncol 2010;27:654-60.
335. Veerla S, Lindgren D, Kvist A et al. MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 2009;124:2236-42.
336. Mill J, Tang T, Kaminsky Z et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008;82:696-711.
337. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 2008;3:e2698.
338. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358: 1148-59.
339. Heng JI, Nguyen L, Castro DS et al. Neurogenin 2 controls cortical neuron migration through regulation of Rnd2. Nature 2008;455:114-18.
340. Pereira MA, Tao L, Liu Y, Li L, Steele VE, Lubet RA. Modulation by budesonide of DNA methylation and mRNA expression in mouse lung tumors. Int J Cancer 2007;120:1150-53.
341. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029-33.
342. Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.
343. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008;283: 1026-33.
344. Zhu SM, Si ML, Wu HL, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007;282:14328-36.
345. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299: 425-36.
346. Bloomston M, Frankel WL, Petrocca F et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901-08.
347. Meng FY, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133: 647-58.
348. Zhang K, Zhang R, Li X, Yin G, Niu X. Promoter methylation status of p15 and p21 genes in HPP-CFCs of bone marrow of patients with psoriasis. Eur J Dermatol 2009; 19:141-46.
349. Furonaka O, Takeshima Y, Awaya H, Ishida H, Kohno N, Inai K. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol Int 2004; 54:549-55.
350. Lindberg D, Akerstrom G, Westin G. Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours. Clin Endocrinol 2008;68:271-77.
351. Kim M, Yim SH, Cho NS et al. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. Cancer Genet Cytogenet 2009;195:59-65.
352. Shimamoto T, Ohyashiki JH, Ohyashiki K. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res 2005;29:653-59.
353. Chen W, Wu Y, Zhu J, Liu J, Tan S, Xia C. Methylation of p16 and p15 genes in multiple myeloma. Clin Med Sci J. 2002;17:101-05.
354. Gallardo F, Esteller M, Pujol RM, Costa C, Estrach T, Servitje O. Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas. Haematologica 2004;89:1401-403.
355. El-Shakankiry NH, Mossallam GI. p15 (INK4B) and E-cadherin CpG island methylation is frequent in Egyptian acute myeloid leukemia. J Egypt Natl Canc Inst 2006;18:227-32.
356. Matsuno N, Hoshino K, Nanri T et al. p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia. Leuk Res 2005;29:557-64.
357. Wemmert S, Bettscheider M, Alt S et al. p15 promoter methylation - a novel prognostic marker in glioblastoma patients. Int J Oncol 2009;34:1743-48.
358. Yalcin A, Serin MS, Emekdas G et al. Promoter methylation of P15(INK4B) gene is possibly associated with parvovirus B19 infection in adult acute leukemias. Int J Lab Hematol 2009;31:407-19.
359. Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lubbert M. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leuk Res 2007;31:497-506.
360. Wong TS, Man MW, Lam AK, Wei WI, Kwong YL, Yuen AP. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer 2003;39:1881-87.
361. Morgan DA, Rahmouni K. Differential effects of insulin on sympathetic nerve activity in agouti obese mice. J Hypertens 2010;28:1913-19.
362. Xiang Z, Proneth B, Dirain ML, Litherland SA, Haskell-Luevano C. Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agoutirelated protein antagonist. Biochemistry 2010;49: 4583-600.
363. Gucev ZS, Tasic V, Jancevska A, Kirovski I. A case of Silver-Russell syndrome (SRS): multiple pituitary hormone deficiency, lack of H19 hypomethylation and favourable growth hormone (GH) treatment response. J Genet 2009;88:239-43.
364. Zeschnigk M, Albrecht B, Buiting K et al. IGF2/H19 hypomethylation in Silver-Russell syndrome and isolated hemihypoplasia. Eur J Hum Genet 2008;16:328-34.
365. Chopra M, Amor DJ, Sutton L, Algar E, Mowat D. Russell-Silver syndrome due to paternal H19/IGF2 hypomethylation in a patient conceived using intracytoplasmic sperm injection. Reprod Biomed Online 2010;20: 843-47.
366. Dammann RH, Kirsch S, Schagdarsurengin U et al. Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma. Int J Oncol 2010;36:171-79.
367. Baba Y, Nosho K, Shima K et al. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology 2010;139:1855-64.
368. Li Y, Meng G, Huang L, Guo QN. Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma. Hum Pathol 2009;40: 1441-47.
369. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002;62:6442-46.
370. Ito Y, Koessler T, Ibrahim AE et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet 2008;17:2633-43.
371. Xi Y, Formentini A, Chien M et al. Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2006;2: 113-21.
372. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61.
373. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99: 15524-29.
374. Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-49.
375. Ambs S, Prueitt RL, Yi M et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008;68:6162-70.
376. Roccaro AM, Sacco A, Thompson B et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669-80.
377. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 MicroRNA family. Cell 2005;120: 635-47.
378. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21: 1025-30.
379. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
380. Sampson VB, Rong NH, Han J et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67: 9762-70.
381. Adams BD, Furneaux H, White BA. The microribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ER alpha) and represses ER alpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007;21:1132-47.
382. Roccaro AM, Jia X, Ngo HT et al. MicroRNA expression in the biology, prognosis, and therapy of waldenstrom macroglobulinemia. Clin Lymphoma Myeloma 2009;9: S126.
383. Dixon-McIver A, East P, Mein CA et al. Distinctive patterns of microrna expression associated with karyotype in acute myeloid leukaemia. PLos One 2008;3:e2141.
384. van Rooij E, Sutherland LB, Liu N et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006;103:18255-60.
385. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circulation Res 2007;100:416-24.